Top Industry Leaders in the Lichen Sclerosus Treatment Market
Invivio Therapeutics receives FDA Fast Track designation for LIT-100 for the treatment of Lichen Sclerosus: In September 2023, Invivio Therapeutics received Fast Track designation for LIT-100, a novel topical steroid foam formulation, highlighting its potential for addressing unmet needs in Lichen Sclerosus treatment.
Galderma launches Mirvaso (desmopressin) for the treatment of Lichen Sclerosus in adults: In June 2023, Galderma received FDA approval and launched Mirvaso, a nasal spray containing desmopressin, offering a non-steroidal option for managing Lichen Sclerosus symptoms.
Bayer announces Phase 2b trial results for JAK inhibitor for Lichen Sclerosus: In May 2023, Bayer announced positive Phase 2b trial results for its JAK inhibitor as a potential treatment for Lichen Sclerosus, indicating promising efficacy and safety profile.
List of Lichen Sclerosus Treatment Key Companies in the Market
- AstraZeneca plc
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Johnson & Johnson Services Inc.
- Merck & Co.Inc.
- Pfizer Inc.
- Sandoz AG (Novartis AG)
- Sanofi S.A.
- Valeant Pharmaceuticals
- Zylera Pharmaceuticals